KR101350826B1 - Composition for the prevention and treatment of diabetes mellitus comprising extracts or fractions of eremochloa ophiuroides as an active ingredient - Google Patents
Composition for the prevention and treatment of diabetes mellitus comprising extracts or fractions of eremochloa ophiuroides as an active ingredient Download PDFInfo
- Publication number
- KR101350826B1 KR101350826B1 KR1020120102684A KR20120102684A KR101350826B1 KR 101350826 B1 KR101350826 B1 KR 101350826B1 KR 1020120102684 A KR1020120102684 A KR 1020120102684A KR 20120102684 A KR20120102684 A KR 20120102684A KR 101350826 B1 KR101350826 B1 KR 101350826B1
- Authority
- KR
- South Korea
- Prior art keywords
- fraction
- diabetes
- extract
- methanol
- ethyl acetate
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 58
- 241000025852 Eremochloa ophiuroides Species 0.000 title claims abstract description 47
- 239000004480 active ingredient Substances 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title description 6
- 239000008280 blood Substances 0.000 claims abstract description 55
- 210000004369 blood Anatomy 0.000 claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- 239000011521 glass Substances 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 235000000346 sugar Nutrition 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 244000025254 Cannabis sativa Species 0.000 claims description 20
- 241000258920 Chilopoda Species 0.000 claims description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 13
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 12
- 239000000401 methanolic extract Substances 0.000 claims description 11
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims 5
- 239000007864 aqueous solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 58
- 239000008103 glucose Substances 0.000 abstract description 58
- 235000013402 health food Nutrition 0.000 abstract description 8
- 239000002032 methanolic fraction Substances 0.000 description 42
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 210000001789 adipocyte Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 238000000605 extraction Methods 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000003178 anti-diabetic effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229940100389 Sulfonylurea Drugs 0.000 description 5
- 239000002285 corn oil Substances 0.000 description 5
- 235000005687 corn oil Nutrition 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012156 elution solvent Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940123208 Biguanide Drugs 0.000 description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- GKLSYIMLZDYQBJ-UHFFFAOYSA-N 2''-O-alpha-rhamnosyl-6-C-(6-deoxy-xylo-hexos-4-ulosyl)-luteolin Natural products OC1C(O)C(O)C(C)OC1OC1C(C=2C(=C3C(=O)C=C(OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)OC(C)C(=O)C1O GKLSYIMLZDYQBJ-UHFFFAOYSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PLAPMLGJVGLZOV-UHFFFAOYSA-N Epi-orientin Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- GKLSYIMLZDYQBJ-HQBRDMKGSA-N Maysin Natural products O([C@H]1[C@@H](O)C(=O)[C@@H](C)O[C@@H]1c1c(O)c2C(=O)C=C(c3cc(O)c(O)cc3)Oc2cc1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 GKLSYIMLZDYQBJ-HQBRDMKGSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- -1 RP-18 Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- GKLSYIMLZDYQBJ-CGOKOBCESA-N maysin Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](C)O[C@@H]1O[C@@H]1[C@@H](C=2C(=C3C(=O)C=C(OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)O[C@@H](C)C(=O)[C@H]1O GKLSYIMLZDYQBJ-CGOKOBCESA-N 0.000 description 2
- PDXPLYCPNXZSAL-UHFFFAOYSA-N maysine Natural products CN1C(=O)C=CC2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 PDXPLYCPNXZSAL-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- ODBRNZZJSYPIDI-UHFFFAOYSA-N 3',4',5,7-tetrahydroxy-6-C-glucopyranosylflavone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WDPQNSQNFBXQCI-AEMKNROXSA-N Derhamnosylmaysin Natural products O=C1[C@@H](O)[C@@H](O)[C@H](c2c(O)c3C(=O)C=C(c4cc(O)c(O)cc4)Oc3cc2O)O[C@H]1C WDPQNSQNFBXQCI-AEMKNROXSA-N 0.000 description 1
- WDPQNSQNFBXQCI-KTMDGTSKSA-N Derhamnosylmaysin Chemical compound OC1[C@@H](O)C(=O)C(C)O[C@@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O WDPQNSQNFBXQCI-KTMDGTSKSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 241001433310 Eremochloa Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- PTNJRKBWIYNFSY-UHFFFAOYSA-N Lirinin-O-methyl-ether Natural products COc1ccc-2c(CC3N(C)CCc4cc(OC)c(OC)c-2c34)c1 PTNJRKBWIYNFSY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- RBVAFYCFAFADAG-UHFFFAOYSA-N Orientin Natural products OCC1OC(C(O)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4)C(O)C1O RBVAFYCFAFADAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- WJJFWGUVMIUWGG-UHFFFAOYSA-N Stereolensin Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O WJJFWGUVMIUWGG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- LQSNPVIQIPKOGP-UHFFFAOYSA-N UNPD159785 Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O LQSNPVIQIPKOGP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- ROQHTXBYBLROKW-UHFFFAOYSA-N derhamnosylmaysin Natural products OC1C(O)C(O)C(C)OC1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ROQHTXBYBLROKW-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- UYJGIAWJIRZBNU-UHFFFAOYSA-N isoorientin Natural products OCC1OC(C(O)C(O)C1O)c2cc(O)c(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4 UYJGIAWJIRZBNU-UHFFFAOYSA-N 0.000 description 1
- ODBRNZZJSYPIDI-VJXVFPJBSA-N isoorientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-VJXVFPJBSA-N 0.000 description 1
- IUYFTHKQEWZTHY-LQQQXCKLSA-N isoorientin 2''-O-rhamnoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)OC1O[C@H]1[C@H](C=2C(=C3C(=O)C=C(OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)O[C@H](CO)[C@@H](O)[C@@H]1O IUYFTHKQEWZTHY-LQQQXCKLSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- HSSGNVITVKZRHD-UHFFFAOYSA-L magnesium octadecanoate octadecanoic acid Chemical compound [Mg++].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HSSGNVITVKZRHD-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- PLAPMLGJVGLZOV-VPRICQMDSA-N orientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-VPRICQMDSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물에 관한 것이다.
The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) relates to a composition for preventing and treating diabetes containing the extract or fractions thereof as an active ingredient.
최근 우리나라도 급속한 경제성장과 생활수준의 향상 및 서구화로 신체발달 측면에서는 매우 바람직한 현상을 보이는 반면, 성인들의 경우 과다한 고칼로리 음 식의 섭취, 운동부족 및 산업사회의 고도화에 따른 스트레스로 인하여 질병양상도 점점 성인병 위주로 서구화되고 있다. 대표적인 성인병의 예로는 간질환, 고혈압, 당뇨병, 비만증, 고지혈증 등을 들 수 있다.Recently, Korea also shows a very desirable phenomenon in terms of physical development due to rapid economic growth, improved living standards, and westernization.In the case of adults, the disease pattern is caused by stress caused by excessive high calorie food intake, lack of exercise and industrial society. Increasingly, the disease is becoming more westernized, especially in adult diseases. Representative adult diseases include liver disease, high blood pressure, diabetes, obesity, hyperlipidemia and the like.
대표적인 성인병의 하나인 당뇨병은 비전염성 만성질환으로, 췌장의 β세포에서 분비되는 인슐린이 부족하거나 그 기능을 제대로 발휘하지 못하여 체내에서 포도당이 에너지원으로 이용되지 못하고 혈액 내에 고농도로 남아 있다가 소변으로 배설되는 질환이다. 당뇨병은 그 발병원인 및 증상의 치료방법에 따라 크게 인슐린 의존형 당뇨병(insulin dependent diabetes mellitus, IDDM)과 인슐린 비의존형 당뇨병(non-insulin dependent diabetes mellitus, NIDDM)으로 분류할 수 있다. 우리나라의 경우 당뇨병 환자의 95% 이상이 NIDDM 환자이다. 당뇨병은 그 자체가 큰 질환이라기 보다는 장기간 이 질환에 걸려 있음으로 해서 발병하는 합병증, 예를 들어 당뇨병성 신경병증(neuropathy), 망막병증(retinopathy), 백내장(cataract), 신장병(nephropathy) 등으로 인해 환자들이 정상적인 삶을 영위할 수 없을 뿐 아니라 치명적인 결과까지 초래할 수 있기 때문에 사회적으로 큰 문제가 되는 것이다.Diabetes, one of the typical adult diseases, is a non-communicable chronic disease. Insulin secreted by the pancreatic β cells is insufficient or does not function properly. Therefore, glucose is not used as an energy source in the body and remains high in the blood. It is a disease that is excreted. Diabetes can be broadly classified into insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) according to its pathogenesis and treatment of symptoms. In Korea, more than 95% of diabetics are NIDDM patients. Diabetes is not a big disease in itself but rather a complication caused by long-term disease, such as diabetic neuropathy, retinopathy, cataract, nephropathy, etc. This is a social problem because patients can not only live a normal life but can have fatal consequences.
현재 흔히 사용되는 당뇨병 치료제는 경구용 혈당강하제와 인슐린 주사제로 크게 구분된다. 일반적으로, 체내에서 인슐린 분비가 없는 인슐린 의존형 당뇨병 환자, 임신성 당뇨병 환자 및 경구용 혈당강하제로 혈당조절이 제대로 안 되는 인슐린 비의존형 당뇨병 환자에게는 인슐린 주사를, 식사용법과 운동요법을 병행함에도 불구하고 적절한 혈당조절이 되지 않는 인슐린 비의존형 당뇨병 환자는 경구용 혈당강하제를 복용하게 하는 것이 일반적이며, 경구용 혈당강하제는 설포닐우레아계 약물과 비구아니드계 약물 등으로 구분될 수 있다.Currently used diabetic drugs are roughly divided into oral hypoglycemic agents and insulin injections. In general, insulin injections for insulin-dependent diabetics without pregnancy in the body, gestational diabetes patients, and insulin-independent diabetes patients whose oral hypoglycemics are poorly controlled are given adequate insulin injections, despite the combination of diet and exercise therapy. Insulin-independent diabetic patients who do not have blood sugar control are generally allowed to take oral hypoglycemic agents, and oral hypoglycemic agents may be classified into sulfonylurea drugs and biguanide drugs.
글리피자이드(glipizide), 글리클라자이드(gliclazide), 글리퀴돈(gliquidone), 글리벤클라마이드(glibenclamide) 및 클로르프로파마이드(chlorpropamide) 등의 설포닐우레아계 약물은 췌장에서 인슐린 분비를 촉진하는 작용을 나타내지만, 췌장에서 인슐린 분비가 전혀 없는 인슐린 의존형 당뇨병 환자에게는 사용할 수 없으며, 췌장에서 인슐린 분비 능력이 상대적으로 감소된 인슐린 비의존형 당뇨병 환자나 기형아 출산, 유산, 사산 등이 우려되므로 가임기 여성에게는 사용할 수 없다는 단점이 있다. 또한, 대부분의 설포닐우레아계 약물은 간에서 대사되어 신장으로 배설되므로 간기능 및 신기능 장해 환자에게는 주의하여 사용하여야 한다.Sulfonylurea-based drugs such as glipizide, gliclazide, gliquidone, glibenclamide, and chlorpropamide have been shown to promote insulin secretion in the pancreas. However, it cannot be used for insulin-dependent diabetics who have no insulin secretion in the pancreas and cannot be used for women of childbearing age due to concerns about insulin-independent diabetes patients with relatively reduced insulin secretion in the pancreas, birth defects, miscarriage, and stillbirth. There are disadvantages. In addition, since most sulfonylurea-based drugs are metabolized in the liver and excreted into the kidney, they should be used with caution in patients with hepatic and renal function disorders.
메트포르민(metformin) 등의 비구아니드계 약물은 작용기전이 분명하지 않지만 췌장에서 인슐린 분비를 증가시키는 작용은 없는 것으로 밝혀져 있으며, 설포닐우레아계 약물보다 혈당강하효과가 약한 반면에, 저혈당을 일으킬 가능성도 낮다. 그러나 소화기계 부작용의 발생빈도가 높아 치료초기에 오심, 구토, 설사, 발진 등 이 나타나며, 젖산혈증(lactic acidosis)을 유발하여 생명을 위협하는 치명적인 부작용을 일으키므로, 현재 미국에서는 실험용 약제로만 사용하고 있다.Although biguanide-based drugs such as metformin have no clear mechanism of action, they have not been shown to increase insulin secretion in the pancreas, and have a lower hypoglycemic effect than sulfonylurea-based drugs. low. However, due to the high incidence of side effects of the digestive system, nausea, vomiting, diarrhea and rash appear at the beginning of treatment, and cause lactic acidosis and cause life-threatening side effects. have.
따라서, 현재 사용되고 있는 설포닐우레아계 또는 비구아니드계의 약물은 상기의 단점이나 부작용이 있으므로 국내외적으로 증가 추세에 있는 당뇨성 질환을 더 바람직하게 치료할 수 있는 보다 부작용이 적고 안전한 혈당강하제를 개발할 필요가 있다.Therefore, currently used sulfonylurea-based or biguanide-based drugs have the above disadvantages or side effects, and therefore, there is a need to develop a safer hypoglycemic agent with less side effects and more desirable to treat diabetic diseases that are increasing at home and abroad. There is.
이와 같이, 현재 화학적으로 합성된 항당뇨제의 여러가지 심각한 부작용의 발생과 함께 약물 내성의 발생으로 인한 약물 효과가 떨어지고 있으므로, 화학합성 항당뇨제를 지양하고 천연물로부터 새로운 항당뇨 활성을 갖는 신규 물질을 찾고자 하는 많은 연구가 진행중이다.
As described above, since the serious effects of chemically synthesized antidiabetics and the drug effects due to the development of drug resistance have been declining, it is necessary to avoid chemosynthetic antidiabetics and find new substances with new antidiabetic activity from natural products. Many studies are in progress.
센티페드그라스(Eremochloa ophiuroides; Centipede grass; 난지형 잔디)는 생육이 늦은 난지형 잔디로서 뗏장을 형성하며 포복 생장을 하는 다년생 잔디이다. 벼과(Poaceae)에 속하며, 학명은 Eremochloa ophiuroides (Munro) Hack이다. 주로 중국과 동아시아, 인도차이나, 미국 북동부, 메소아메리카와 캐러비안 지역에 분포하고 있으며, 각종 토양조건에 폭 넓게 잘 적응되지만, 특히 습하며 산성토양 및 비옥도가 낮은 사질 토양에서 잘 견딘다. 형태학적 특징으로서, 잎은 길이 15~30 ㎜, 폭 2~4 ㎜이고, 흰 중심맥(mid vein)을 가지는 납작한 모양이며, 경령(collar) 부분을 제외하고 털이 없고, 잎 끝부분은 둥글다. 줄기는 아주 굳게 다문 잎집(sheath)을 가지고, 뿌리는 가는 분기형의 포복경(stolons)이다. 꽃 부분은 3~5 인치 정도의 하나의 총상화서(總狀花序, raceme, = 총상꽃차례)를 가지고, 상기 총상화서는 자줏빛색을 띠고 약간 평평하며 두 줄로 배열된 작은 이삭(小穗, spikelet)을 가진다. 주용도는 잔디 밭 또는 뗏장 잔디로 사용되고 높은 잎의 비율(leafiness)과 좋은 맛 때문에 조사료로 이용된다. Sentipedgrass ophiuroides ; Centipede grass; Nanji turf) is a late-turf turf that is a perennial grass that crawls and forms a turf. Belongs to Poaceae, scientific name is Eremochloa ophiuroides (Munro) Hack. It is mainly distributed in China, East Asia, Indochina, Northeastern USA, Mesoamerica and the Caribbean. It is well adapted to various soil conditions, but it is particularly resistant to moist and acid soil and low fertility soil. As a morphological feature, the leaf has a length of 15 ~ 30 ㎜, a width of 2 ~ 4 ㎜, a flat shape with a mid vein, no hairs except a collar part, and a leaf tip round. The stem is a branching type stolons with a very firmly sheath (sheath). The flower part has a three to five inches long fossil flower (raceme), which has a purple color and a slightly flat, spikelet arranged in two lines. I have. It is used as a lawn or turf grass and is used as a forage for its leafiness and good taste.
센티페드그라스(난지형 잔디)는 현재 비만 예방 및 치료, 암예방 및 치료, 피부 노화 방지, 피부 미백 등의 용도에 대한 연구가 있어 왔다. 그러나 아직까지 센티페드그라스의 여러 성분들 중에서 어떠한 성분이 어떠한 약리적인 효과를 나타내는지에 대한 구체적이고 체계적인 연구 결과는 보고된 바 없으며, 특히 당뇨성 질환에 대한 치료효능과 관련된 어떠한 보고도 없는 실정이다.
Sentipedgrass (warm turf grass) has been researched for the purpose of preventing and treating obesity, preventing and treating cancer, preventing skin aging, skin whitening and the like. However, there have been no specific and systematic studies on which pharmacological effects among the various components of centipedegrass have been reported. In particular, there are no reports regarding the therapeutic efficacy of diabetic diseases.
이에, 본 발명자들은 당뇨병 치료 활성이 뛰어난 천연 식물 추출물을 연구하던 중, 센티페드그라스에서 추출한 추출물, 이의 분획물 및 상기 분획물로부터 분리한 활성분획이 혈중 당 농도를 효과적으로 조절함으로써 새로운 당뇨병 치료제로 활용될 수 있음을 밝힘으로써 본 발명을 완성하였다.
Therefore, while the present inventors are studying natural plant extracts having excellent anti-diabetic activity, the extracts extracted from Sentedgrass, fractions thereof, and active fractions separated from the fractions can be effectively used as new diabetes therapeutic agents by effectively controlling blood glucose levels. The present invention has been completed by revealing that there is.
본 발명의 목적은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물을 제공하는 것이다.
An object of the present invention is to provide a composition for the prevention and treatment of diabetes mellitus containing Centipede grass ( Eremochloa ophiuroides ) extract or a fraction thereof as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the prevention and treatment of diabetes containing Centipede grass (Centipede grass, Eremochloa ophiuroides ) extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스 추출물을 유효성분으로 함유하는 당뇨병 예방 또는 개선용 기능성 식품을 제공한다.In order to achieve the above object, the present invention provides a functional food for preventing or improving diabetes containing centipede glass extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스 추출물을 유효성분으로 함유하는 혈당 강하 조절용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for controlling blood sugar drop containing centipede glass extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스 추출물을 유효성분으로 함유하는 혈당 강하 조절용 건강식품을 제공한다.
In order to achieve the above object, the present invention provides a health food for controlling blood sugar drop containing centipede glass extract as an active ingredient.
본 발명의 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획은 독성이 없는 천연물로서 혈중 당 농도를 효과적으로 조절함으로써 새로운 당뇨병 예방 또는 치료용 조성물, 또는 기능성 식품으로 유용하게 사용될 수 있다.
Centipedgrass extract, fractions thereof, or active fractions separated from the fractions of the present invention can be usefully used as a novel diabetic prevention or treatment composition, or as a functional food by effectively controlling blood glucose concentrations as non-toxic natural products.
도 1은 본원발명의 센티페드그라스의 추출물, 이의 분획물 및 상기 분획물로부터 분리한 활성분획을 제조하는 과정을 나타낸 도식도이다.
도 2는 도 3의 지방 축적 정도를 수치화시켜서 나타낸 그림이다.
도 3은 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 지방세포의 당대사과정을 통해 생성되는 지방축적정도를 나타낸 그림이다.
도 4는 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 2형 당뇨 마우스에서 혈당 강하 활성을 가지는 것을 확인한 그림이다.
도 5는 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 2형 당뇨 마우스에서 항당뇨 실험의 결과를 확인한 그림이다.
도 6은 2형 당뇨 마우스에서 글루코스 경구 부화 실험을 하여 혈당 변화를 확인한 그림이다.
도 7은 센티페드그라스 에틸아세테이트-메탄올 분획물의 투여량을 1㎎/㎏ 및 10㎎/㎏하여 글루코스 경구 부하 실험을 한 결과를 나타낸 그림이다.
도 8은 센티페드그라스 에틸아세테이트-메탄올 분획물의 투여량을 1㎎/㎏ 및 10㎎/㎏하여 복강내 당 부하를 검사한 결과를 나타낸 그림이다.
도 9는 센티페드그라스 에틸아세테이트-메탄올 분획물을 복강 투여한 다음 글루코스 경구 부하 실험을 하여 혈당 변화를 확인한 그림이다.
도 10은 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 스트렙토조토신( STZ)-제 1형 당뇨 유도 모델에서 항당뇨 활성을 글루코스 경구 부하 실험을 하여 혈당 변화를 확인한 그림이다. 1 is a schematic diagram showing a process of preparing an extract of Sentipedgrass, fractions thereof, and active fractions separated from the fractions of the present invention.
FIG. 2 is a diagram showing the amount of fat accumulation in FIG.
Figure 3 is a diagram showing the degree of fat accumulation produced by the glucose metabolism process of fat cells by the centipede glass ethyl acetate- methanol fraction.
Figure 4 is a picture confirming the hypoglycemic activity in
Figure 5 is a picture confirming the results of the anti-diabetic experiment in
6 is a diagram confirming the change in blood glucose by oral glucose experiment in
FIG. 7 shows the results of glucose oral loading experiments using the doses of the centifed glass ethyl acetate-methanol fraction at 1 mg / kg and 10 mg / kg.
8 is a diagram showing the results of the intraperitoneal
Figure 9 is a diagram confirming the change in blood glucose by intraperitoneal administration of the centifed glass ethyl acetate- methanol fraction and then oral glucose loading test.
Figure 10 is a figure confirming the change in blood glucose by oral glucose tolerance test anti-diabetic activity in the streptozotocin (STZ)
이하, 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물을 제공한다.The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) provides a composition for preventing and treating diabetes containing the extract as an active ingredient.
상기 센티페드그라스 추출물은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다: The centipedlass extract is preferably, but not exclusively, prepared by a process comprising the steps of:
1) 센티페드그라스에 추출용매를 가하여 추출하는 단계;1) extracting Sentipedgrass with an extraction solvent;
2) 단계 1)의 추출물을 식힌 후 여과하는 단계; 및2) cooling the extract of step 1) and filtering; And
3) 단계 2)의 여과한 추출물을 감압농축하는 단계.3) Concentrating the filtered extract of step 2) under reduced pressure.
상기 방법에 있어서, 단계 1)의 센티페드그라스는 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 센티페드그라스는 잎, 줄기 또는 뿌리를 모두 이용할 수 있으나, 잎을 이용하는 것이 바람직하다.In the above method, the centipedegrass of step 1) may be used without limitation such as grown or commercially available. The centipedegrass may be a leaf, a stem, or a root, but leaves are preferably used.
상기 제조방법에 있어서, 단계 1)의 추출용매는 물, 알코올 또는 이들의 혼합물인 것이 바람직하고, 상기 알코올로는 C1 내지 C2 저급 알코올을 이용하는 것이 바람직하며, 저급 알코올로는 에탄올 또는 메탄올을 이용하는 것이 바람직하고, 메탄올을 이용하는 것이 더욱 바람직하나 이에 한정되지 않는다. 추출방법으로는 진탕추출 또는 환류추출을 이용하는 것이 바람직하나 이에 한정하지 않는다. 상기 추출용매를 건조된 센티페드그라스의 총 분량에 2 내지 10배 첨가하여 추출하는 것이 바람직하며, 10배 첨가하여 추출하는 것이 더욱 바람직하나 이에 한정되지 않는다. 또한, 추출온도는 50 내지 120℃인 것이 바람직하며, 40 ~ 45℃인 것이 더욱 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 2 내지 5일인 것이 바람직하나 이에 한정하지 않는다. 아울러, 추출 회수는 1 내지 3회인 것이 바람직하나 이에 한정되는 것은 아니다.In the above production method, the extraction solvent of step 1) is preferably water, alcohol or a mixture thereof, and the alcohol is preferably C 1 To C 2 lower alcohol is preferably used. As the lower alcohol, ethanol or methanol is preferably used, and methanol is more preferably used, but not limited thereto. As the extraction method, it is preferable to use shaking extraction or reflux extraction, but it is not limited thereto. The extraction solvent is preferably added by 2 to 10 times the total amount of the dried centipedgrass, more preferably by 10 times, but not limited thereto. In addition, the extraction temperature is preferably 50 to 120 ° C, more preferably 40 to 45 ° C, but is not limited thereto. The extraction time is preferably 2 to 5 days, but is not limited thereto. In addition, the number of times of extraction is preferably 1 to 3 times, but is not limited thereto.
상기 방법에 있어서, 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 상기 감압농축은 20 ~ 60℃에서 농축하는 것이 바람직하고 45 ~ 55℃에서 농축하는 것이 바람직하나 이에 한정되지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않는다. 상기 동결건조는 -50 ~ -100℃에서 건조하는 것이 바람직하고 -70℃에서 건조하는 것이 바람직하나 이에 한정되지 않는다.In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. The reduced pressure concentration is preferably concentrated at 20 ~ 60 ℃ and preferably concentrated at 45 ~ 55 ℃ is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto. The above-mentioned freeze-drying is preferably performed at -50 to -100 ° C, and drying is preferably performed at -70 ° C, but is not limited thereto.
상기 방법에 있어서, 센티페드그라스 추출물은 열수로 추출하는 것이 바람직하나 이에 한정되지 않는다. In the above method, the centipedes grass extract is preferably extracted with hot water, but is not limited thereto.
본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물을 제공한다.The present invention provides a composition for the prevention and treatment of diabetes containing the organic solvent fraction prepared by extracting the centipedes glass extract with an organic solvent as an active ingredient.
본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물을 제공한다. The present invention provides a composition for the prevention and treatment of diabetes comprising the active fraction obtained by separating the fraction of centipedegrass extract by column chromatography as an active ingredient.
상기 센티페드그라스 추출물의 분획물 또는 상기 분획물로부터 분리한 활성분획은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다:The fraction of the centipedlass extract or the active fraction isolated from the fraction is preferably, but not necessarily, prepared by a process comprising the steps of:
1) 센티페드그라스 추출물에 추가로 유기용매를 가하여 유기용매 분획물을 제조하는 단계; 및1) preparing an organic solvent fraction by adding an organic solvent to the centipede glass extract; And
2) 단계 1)의 분획물을 컬럼크로마토그래피를 실시하여 활성분획을 제조하는 단계.2) Performing column chromatography on the fraction of step 1) to produce an active fraction.
상기 방법에 있어서, 단계 1)의 유기용매는 n-헥산 또는 에틸아세테이트인 것이 바람직하나 이에 한정하지 않는다.In the above method, the organic solvent in step 1) is preferably, but not limited to, n-hexane or ethyl acetate.
상기 방법에 있어서, 상기 유기용매 분획물은 센티페드그라스 메탄올 추출물을 n-핵산으로 추출한 후 가용층을 제거한 남은 물층을 에틸아세테이트로 추출한 에틸아세테이트 분획물인 것이 바람직하나 이에 한정하지 않는다.In the above method, the organic solvent fraction is preferably an ethyl acetate fraction obtained by extracting the centifed glass methanol extract with n-nucleic acid and then removing the soluble layer with ethyl acetate.
상기 방법에 있어서, 단계 2)의 컬럼크로마토그래피는 실리카겔, 세파덱스, RP-18, 폴리아미드, 도요펄(Toyopearl) 및 XAD 수지로 이루어진 그룹으로부터 선택된 충진제를 이용한 컬럼크로마토그래피를 수행하여 활성분획을 분리 및 정제할 수 있다. 컬럼크로마토그래피는 필요에 따라 적절한 충진제를 선택하여 수차례 실시할 수 있다. In this method, the column chromatography of step 2) is carried out by column chromatography using a filler selected from the group consisting of silica gel, Sephadex, RP-18, polyamide, Toyopearl and XAD resin to obtain an active fraction Can be separated and purified. The column chromatography can be carried out several times by selecting an appropriate filler as necessary.
상기 방법에 있어서, 단계 2)의 센티페드그라스 추출물의 에틸아세테이트 분획물을 추가적으로 컬럼크로마토그래피에 흡착시키고 메탄올을 용출용매로 사용하여 활성분획을 분리시에 사용하는 상기 메탄올은 20 내지 70% 메탄올인 것이 바람직하다. 구체적으로, 본 발명자들은 센티페드그라스의 에틸아세테이트 분획물을 Flex-ColumTM(3 ㎝ × 25 ㎝) 및 도요펄(Toyoperarl) HW-40(75 ㎛) 컬럼크로마토그래피에 흡착시키고 20, 50 또는 70% 메탄올 용출용매를 사용하여, 에틸아세테이트-20%메탄올, 에틸아세테이트-50%메탄올 및 에틸아세테이트-70%메탄올 활성분획을 얻었다.
In the above method, the ethyl acetate fraction of the centifed glass extract of step 2) is additionally adsorbed to column chromatography, and methanol is used as elution solvent. desirable. Specifically, we adsorbed the ethyl acetate fraction of centifedgrass to Flex-Colum ™ (3 cm × 25 cm) and Toyoperarl HW-40 (75 μm) column chromatography and adsorbed 20, 50 or 70%. Using methanol eluting solvent, ethyl acetate-20% methanol, ethyl acetate-50% methanol and ethyl acetate-70% methanol active fractions were obtained.
본 발명자들은 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 지방세포의 포도당의 지방 전환 분석하기 위하여 지방세포주(3T3-L1 Preadipocyte cell line)을 이용하여 에틸아세테이트-50% 및 70%메탄올 분획물이 지방세포에 의한 포도당 흡수 효과를 증진시키는지를 측정한 결과 낮은 농도의 인슐린이 처리된 군을 기준으로 하였을 때, 에틸아세테이트-50%메탄올 분획물을 100 ㎍/ml 처리한 군에서 지방세포 내 지방 축적되는 정도가 약 300% 이상 증가하였고(도 2 및 도 3 참조), 세티페드그라스 추출 분획물이 2형 당뇨마우스(db / db 마우스)에 혈당 강하 활성을 확인한 결과 센티페디그라스 에틸아세테이트-50% 및 70%메탄올 분획물을 열흘간 처리한 군은 당뇨 유발군과 비교하여 70~80%의 혈당 강하효과를 나타내는 것을 확인할 수 있고, 샘플처리를 중단함으로써 마우스의 혈당이 다시 상승하였으며(도 4 참조), 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 글루코스 경구 부하 실험(Oral Glucose Tolerance test, OGTT) 분석한 결과 센티페디그라스 에틸아세테이트-메탄올 분획물을 처리한 마우스는 혈당의 급격한 상승을 비교군과 비교하였을 때 약 25% 감소시켰고, 150분 후 혈당강하 정도가 비교군에 비해 약 60%증가 시키는 것을 확인하였고(도 5 및 도 6 참조), 센티페드그라스 에틸아세테이트-메탄올 분획물의 투여량을 다르게하여 글루코스 경구 부하 실험을 한 결과 티페디그라스 에틸아세테이트-50%메탄올 분획물을 처리한 군이 비교군에 비해 60분 후 혈당이 급격히 상승하는 것을 고농도에서는 40%, 저농도에서는 60% 수준으로 유지하는 것을 확인하였으며(도 7 참조), 센티페드그라스 에틸아세테이트-메탄올 분획물의 투여량을 다르게하여 복강내 당 부하 검사(Intraperitoneal tolerance test, IPGTT) 분석을 한 결과 센티페디그라스 에틸아세테이트-50%메탄올 분획물을 고농도 및 저농도로 처리한 군을 비교군과 비교를 하였을 때, 2시간 후 혈당강하 정도가 약 80% 증가되는 것을 확인하였고(도 8 참조), 센티페드그라스 에틸아세테이트-메탄올 분획물을 복강 투여한 다음 글루코스 경구 부하 실험 분석을 한 결과 4시간 30분이 지난 시점에서 대조군의 혈당은 400 mg/dL이상으로 유지되고 있지만, 센티페디그라스 에틸아세테이트-50%메탄올 분획물을 처리한 군의 혈당은 250 mg/dL이하까지 떨어졌다. 이것은 대조군과 비교하여 혈당강하 정도가 약 60% 증가하였으며(도 9 참조), 센티페드그라스 에틸아세테이트-메탄올 분획물에 의한 스트렙토조토신( STZ)-제 1형 당뇨 유도 모델에서 항당뇨 활성 분석을 한 결과 센티페디그라스 에틸아세테이트-메탄올 분획물을 처리한 군은 4시간 30분이 지나는 시점부터 혈당이 정상군과 같은 정도까지 떨어지는 것을 확인할 수 있다. 하지만, 대조군은 6시간이 지나도 정상군보다 150 mg/dL이상 높게 유지되고, 글루코스를 투여하고 6 시간 후 센티페디그라스 에틸아세테이트-메탄올 분획물을 처리한 군은 대조군과 비교하여 100% 혈당 강하시켰다(도 10 참조).In order to analyze the fat conversion of glucose from adipocytes by the centifed glass ethyl acetate-methanol fraction, the present inventors investigated the ethyl acetate-50% and 70% methanol fractions in adipocytes using a 3T3-L1 Preadipocyte cell line. As a result of measuring glucose uptake effect, the level of fat accumulation in adipocytes was low in the group treated with 100 ㎍ / ml of ethyl acetate-50% methanol fraction based on the group treated with low concentration of insulin. It was increased by more than 300% (see Fig. 2 and 3), Cetidegrass extract fractions confirmed the hypoglycemic activity in
따라서, 센티페드그라스에서 추출한 추출물, 이의 분획물 및 상기 분획물로부터 분리한 활성분획이 혈중 당 농도를 효과적으로 조절함을 확인함으로써 당뇨병 예방 및 치료용 조성물, 및 당뇨병 예방 또는 개선용 기능성 식품, 혈당 강하 조절용 약학적 조성물 및 혈당 강하 조절용 건강식품으로 유용하게 사용될 수 있다.
Therefore, by confirming that the extract extracted from Sentipedgrass, fractions thereof, and active fractions separated from the fractions effectively regulate blood glucose levels, the composition for preventing and treating diabetes, and the functional food for preventing or improving diabetes, and the pharmaceutical for controlling blood sugar drop It can be usefully used as a red blood composition and health food for controlling blood sugar drop.
본 발명의 당뇨병 예방 및 치료용 약학적 조성물에 있어서, 상기 당뇨병은 제 1형 당뇨병 또는 제 2형 당뇨병인 것이 바람직하나, 이에 한정되지 않는다.In the pharmaceutical composition for preventing and treating diabetes of the present invention, the diabetes is preferably
본 발명은 센티페드그라스 추출물을 유효성분으로 함유하는 혈당 강하 조절용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for controlling blood sugar drop, which contains the centipedegrass extract as an active ingredient.
본 발명의 약학적 조성물은 독성 및 부작용은 거의 없으므로 장기간 복용 시에도 안심하고 사용할 수 있는 조성물이다.
Since the pharmaceutical composition of the present invention has little toxicity and side effects, it is a composition that can be used safely even when taken for a long time.
본 발명의 약학적 조성물은 통상적으로 사용되는 부형제, 붕해제, 감미제, 활택제, 향미제 등을 추가로 포함할 수 있으며, 통상적인 방법에 의해 정제, 캅셀제, 산제, 과립제, 현탁제, 유제, 시럽제, 기타 액제로 제형화될 수 있다.The pharmaceutical composition of the present invention may further contain commonly used excipients, disintegrants, sweeteners, lubricants, flavors and the like, and may be formulated into tablets, capsules, powders, granules, suspensions, Syrups, and other liquid preparations.
구체적으로 본 발명의 약학적 조성물은 경구 투여용 제형, 예를 들면 정체, 트로치제(troches), 로젠지(lozenge), 수용성 또는 우성현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제(elixirs)로 제제화된다. 정제 및 캡슐 등의 제형으로 제제하기 위해 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀롤로오스 또는 젤라틴과 같은 결합제, 디칼슘 포스페이트와 같은 부형제, 옥수수 전분 또는 고구마 전분과 같은 붕해제, 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유가 함유된다. 캡슐제형의 경우는 상기에서 언급한 물질 이외에도 지방유와 같은 액체 담체를 함유한다.Specifically, the pharmaceutical compositions of the present invention can be formulated for oral administration, for example, as tablets, troches, lozenges, aqueous or aqueous suspensions, prepared powders or granules, emulsions, hard or soft capsules, It is formulated into elixirs. Binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, celluloses or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, and disintegrants such as stearic acid Magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax. In the case of a capsule formulation, in addition to the above-mentioned substances, a liquid carrier such as fatty oil is contained.
또한, 본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다. 비경구 투여용 제형으로 제제화하기 위해서는 본 발명의 센티페드그라스 추출물, 이의 분획물 또는 분획물의 활성분획을 안정제 또는 완충제와 함께 물에서 혼합하여 현탁액으로 제조하고 이를 앰플 또는 바이알의 단위 투여형으로 제제한다.In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally, and it is preferable to select subcutaneous injection, intravenous injection, intramuscular injection, or intra-thoracic injection injection method for parenteral administration. In order to formulate the formulation for parenteral administration, the active fraction of the centipede glass extract, fraction or fraction thereof of the present invention is mixed with water with a stabilizer or a buffer to prepare a suspension, which is formulated into a unit dosage form of ampoule or vial.
본 발명에 따른 유효성분의 투여량은 체내에서 활성성분의 흡수도, 불활성화율 및 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증 정도에 따라 적절히 선택되나, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1 ㎏당 본 발명의 추출물을 0.0001 ~ 500 ㎎의 양으로 1회 내지 수회 나누어 투여할 수 있으며, 0.001 ~ 100 ㎎의 양으로 투여하는 것이 바람직하다.
The dosage of the active ingredient according to the present invention is appropriately selected depending on the degree of absorption, inactivation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, and severity of the disease to be treated. The extract of the present invention may be administered to an adult in an amount of 0.0001-500 mg per 1 kg of body weight per day, preferably in an amount of 0.001-100 mg per one kg of body weight.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 당뇨병 예방 또는 개선용 기능성 식품을 제공한다.The present invention relates to the use of Centipede grass ( Eremochloa It provides a functional food for preventing or improving diabetes containing ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 당뇨병 예방 또는 개선용 기능성 식품을 제공한다. In addition, the present invention provides a functional food for preventing or improving diabetes containing the organic solvent fraction prepared by extracting the centipedes glass extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 당뇨병 예방 또는 개선용 기능성 식품을 제공한다. In another aspect, the present invention provides a functional food for preventing or improving diabetes containing the active fraction of the centifed glass extract additionally separated by column chromatography as an active ingredient.
본 발명의 건강식품에 있어서 상기 당뇨병은 상기 당뇨병은 제 1형 당뇨병 또는 제 2형 당뇨병인 것이 바람직하나, 이에 한정되지 않는다.In the health food of the present invention, the diabetes is preferably diabetes,
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 혈당 강하 조절용 건강식품을 제공한다. The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) Provides a health food for controlling blood sugar drop containing the extract as an active ingredient.
본 발명의 건강식품은 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The health food of the present invention may be added to the centipede glass extract, its fraction or the active fraction isolated from the fraction as it is, or may be used together with other food or food ingredients, and may be suitably used according to a conventional method.
상기 식품의 종류에는 특별한 제한은 없다. 상기 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.
There is no particular limitation on the kind of the food. Examples of the food to which the centipedegrass extract, the fraction thereof, or the active fraction isolated from the fraction can be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gum, ice cream , Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
이하, 본 발명을 실시예, 실험예, 비교예 및 제조예에 의하여 상세히 설명한다. Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples, Comparative Examples and Preparation Examples.
단, 하기 실시예, 실험예, 비교예 및 제조예는 본 발명을 구체적으로 예시하는 것이며, 본 발명의 내용이 실시예, 실험예, 비교예 및 제조예에 의해 한정되는 것은 아니다.
However, the following Examples, Experimental Examples, Comparative Examples and Preparation Examples illustrate the present invention concretely, and the contents of the present invention are not limited by Examples, Experimental Examples, Comparative Examples and Preparation Examples.
<< 실시예Example 1> 1> 센티페드그라스Sentiped Grass 추출물의 제조 Preparation of extract
<1-1> <1-1> 센티페드그라스Sentiped Grass 메탄올 추출물의 제조 Preparation of methanol extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -80℃에 보관하여 사용하였다. 센티페드그라스 잎 5 ㎏을 100% 메탄올(MeOH) 20 ℓ를 첨가하여 믹서기로 마쇄한 후 상온에서 3일간 침지시켜 얻은 추출물을 50℃에서 감압 농축하여 210 g의 센티페드그라스 메탄올 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. Leaf samples were stored at -80 ° C. 5 kg of Centipede grass leaf was added with 20 L of 100% methanol (MeOH), ground with a blender, immersed at room temperature for 3 days, and then concentrated under reduced pressure at 50 캜 to obtain 210 g of a centipede glass methanol extract.
<1-2> <1-2> 센티페드그라스Sentiped Grass 에탄올 추출물의 제조 Preparation of ethanol extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -80℃에 보관하여 사용하였다. 센티페드그라스 잎 5 ㎏을 100% 에탄올(EtOH) 20 ℓ를 첨가하여 믹서기로 마쇄한 후 상온에서 3일간 침지시켜 얻은 추출물을 50℃에서 감압 농축하여 203 g의 센티페드그라스 에탄올 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. Leaf samples were stored at -80 ° C. 5 kg of centipedegrass leaves were added with 20 L of 100% ethanol (EtOH), ground with a blender, immersed in the liquid at room temperature for 3 days, and concentrated under reduced pressure at 50 DEG C to obtain 203 g of a centipede glass ethanol extract.
<1-3> <1-3> 센티페드그라스Sentiped Grass 물 추출물의 제조 Preparation of water extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -8℃에 보관하여 사용하였다. 센티페드그라스 잎 5 ㎏을 물 20 ℓ를 첨가하여 믹서기로 마쇄한 후 상온에서 3일간 침지시켜 얻은 추출물을 50℃에서 감압 농축하여 198 g의 센티페드그라스 물 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. The collected leaf samples were stored at -8 ° C. 20 ℓ of water was added to 5 ㎏ of centipedegrass, and the mixture was ground with a blender and then immersed at room temperature for 3 days. The extract was concentrated under reduced pressure at 50 캜 to obtain 198 g of centipede water extract.
<1-4> <1-4> 센티페드그라스Sentiped Grass 열수Heat number 추출물의 제조 Preparation of extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -8℃에 보관하여 사용하였다. 센티페드그라스 잎 40 g을 물 40 ℓ를 첨가하여 90℃에서 6시간 이상 침지시켜 87 g의 센티페드그라스 열수 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. The collected leaf samples were stored at -8 ° C. 40 g of Centipedgrass leaves were added to 40 L of water and soaked at 90 DEG C for at least 6 hours to obtain 87 g of Centipedgrass hydrothermal extract.
<< 실시예Example 2> 2> 센티페드그라스Sentiped Grass 분획물의Fraction 제조 Produce
상기 실시예 <1-1>에서 수득한 센티페드그라스 메탄올 추출물을 유기용매를 사용하여 극성에 따른 분획을 실시하였다.
The centifed glass methanol extract obtained in Example <1-1> was fractionated according to polarity using an organic solvent.
<2-1> n-<2-1> n- 헥산Hexane 분획물의Fraction 제조 Produce
먼저 <도 1>과 같이, 센티페드그라스의 100% MeOH 추출물의 감압농축한 것을 물에 현탁한 후, 저극성용매인 헥산(N-Hexane)으로 먼저 추출하였다.
First, as shown in FIG. 1, the concentrated concentrate under reduced pressure of 100% MeOH extract of centifed grass was suspended in water, followed by extraction with hexane (N-Hexane), which is a low polar solvent.
<2-2> 에틸아세테이트 <2-2> Ethyl acetate 분획물의Fraction 제조 Produce
상기 실시예 <2-1>의 헥산 추출의 물층을 다시 에틸아세테이트(EtOAc)로 분획하였다.
The water layer of hexane extraction of Example <2-1> was again partitioned with ethyl acetate (EtOAc).
<2-3> 물 <2-3> Water 분획물의Fraction 제조 Produce
상기 실시예 <2-2>에서 n-헥산 및 에틸아세테이트(EtOAc)로 분획한 후 물에 의한 가용 분획물을 마지막으로 수득하였다. 각 용매추출 분획을 감압농축하여 건조시킨 후, 에틸아세테이트 분획물(21 g)을 얻었다.
In Example < 2-2 > in the above Example, fractionation with n-hexane and ethyl acetate (EtOAc) was carried out and finally a soluble fraction with water was obtained. The solvent-extracted fractions were concentrated under reduced pressure and dried to obtain an ethyl acetate fraction (21 g).
<< 실시예Example 3> 3> 센티페드그라스Sentiped Grass 활성분획의 제조 Production of active fractions
<3-1> 에틸아세테이트-20%메탄올 <3-1> ethyl acetate-20% methanol 분획물의Fraction 제조 Produce
상기 <실시예 2>의 에틸아세테이트 분획물을 20% 메탄올을 용출용매로 사용하여 Flex-Colum TM(3 ㎝×25 ㎝)과 Toyoperarl HW-40(75 ㎛)를 사용하여 컬럼크로마토그래피를 실시하여 활성분획물을 수득하였다. 에틸아세테이트-20%메탄올 9.41 g의 활성분획을 수득하였다.
The ethyl acetate fraction of Example 2 was dissolved in Flex-Colum TM (3 cm x 25 cm) using 20% methanol as elution solvent, Column chromatography was performed using Toyoperarl HW-40 (75 占 퐉) to obtain an active fraction. An active fraction of 9.41 g of ethyl acetate-20% methanol was obtained.
<3-2> 에틸아세테이트-50%메탄올 <3-2> ethyl acetate-50% methanol 분획물의Fraction 제조 Produce
상기 <실시예 2>의 에틸아세테이트 분획물을 50% 메탄올을 용출용매로 사용하여 Flex-Colum TM(3 ㎝×25 ㎝)과 Toyoperarl HW-40(75 ㎛)를 사용하여 컬럼크로마토그래피를 실시하여 활성분획물을 수득하였다. 에틸아세테이트-50%메탄올 5.74 g의 활성분획을 수득하였다.
The ethyl acetate fraction of Example 2 was dissolved in Flex-Colum TM (3 cm x 25 cm) using 50% methanol as elution solvent, Column chromatography was performed using Toyoperarl HW-40 (75 占 퐉) to obtain an active fraction. An active fraction of 5.74 g of ethyl acetate-50% methanol was obtained.
<3-3> 에틸아세테이트-70%메탄올 <3-3> ethyl acetate-70% methanol 분획물의Fraction 제조 Produce
상기 <실시예 2>의 에틸아세테이트 분획물을 70% 메탄올을 용출용매로 사용하여 Flex-Colum TM(3 ㎝×25 ㎝)과 Toyoperarl HW-40(75 ㎛)를 사용하여 컬럼크로마토그래피를 실시하여 활성분획물을 수득하였다. 에틸아세테이트-70% 메탄올 1 g의 활성분획을 수득하였다.
The ethyl acetate fraction of Example 2 was dissolved in Flex-Colum TM (3 cm x 25 cm) using 70% methanol as elution solvent, Column chromatography was performed using Toyoperarl HW-40 (75 占 퐉) to obtain an active fraction. Ethyl acetate - 1 g of active fraction with 70% methanol was obtained.
<3-4> 에틸아세테이트-30% 및 70%메탄올 <3-4> Ethyl acetate-30% and 70% methanol 분획물의Fraction 성분 분석 Component analysis
센티페드그라스 추출물의 상기 분획물, 상기 에틸아세테이트-30% 및 70%메탄올 분획물의 부분 분획물의 성분중에서 메이신(maysin) 및 그 유도체의 함량을 분석하였다. 구체적으로, Agilent Technologies 1200 series HPLC에 20 ㎕의 시료 용액을 주입하고, 1% 포름산(용액 A) 및 100% 메탄올(용액 B)로 구성된 이동상을 사용하였다. 상기 이동상을 복합 공정(combined step) 및 30분 동안 100:0(용액 A:B)에서 50:50의 직선 구배로, 이어서 60분 동안 50:50에서 0:100의 직선 구배로 분획물 성분을 용출시켰다. 유속은 0.5 ㎖/min이고 용출된 화합물은 360 ㎚의 파장에서 탐지하였다. 그 결과, 용출된 메이신 및 그 유도체의 함량을 하기 표 1에 기재하였다.
The contents of maysin and its derivatives were analyzed in the components of the fractions of the centifedgrass extract, partial fractions of the ethyl acetate-30% and 70% methanol fractions. Specifically, 20 μl of sample solution was injected into Agilent Technologies 1200 series HPLC and a mobile phase consisting of 1% formic acid (solution A) and 100% methanol (solution B) was used. The mobile phase is eluted with a 50:50 linear gradient at 100: 0 (solution A: B) in a combined step and 30 minutes, followed by a 50:50 linear gradient at 50:50 for 60 minutes. I was. The flow rate was 0.5 ml / min and the eluted compound was detected at a wavelength of 360 nm. As a result, the contents of eluted macine and its derivatives are shown in Table 1 below.
<< 실험예Experimental Example 1> 1> 센티페드그라스Sentiped Grass 에틸아세테이트-메탄올 Ethyl acetate-methanol 분획물에In the fraction 의한 지방세포의 포도당의 지방 전환 분석 Fat conversion analysis of glucose by fat cells
지방세포주(3T3-L1 Preadipocyte cell line)을 이용하여 에틸아세테이트-50% 및 70%메탄올 분획물이 지방세포에 의한 포도당 흡수 효과를 증진시키는지를 측정하였다. 구체적으로, 지방 세포주는 American Type Culture Collect(ATCC)에서 구입하였고, 상기 지방세포(3T3-L1)를 6 웰 플레이트(well plate)에 1×106 개가 되도록 넣고, 세포가 90%까지 자랄 수 있게 CO2 배양기에서 24시간 동안 배양하였다. 그리고 배양중인 배지를 버리고 지방세포로 분화를 도와주는 다른 배지를 넣어 48시간 동안 지방세포로의 분화를 유도하였다. 지방세포 분화를 도와주는 배지의 조성은 10% FBS, 0.5 mM 3-아이소부틸(isobutyl)-1-메틸크산틴(methylxanthine)(IBMX), 10 nm/ml 인슐림(insulin), 1 μM 덱사메타손(dexamethasone)이 들어있는 DMEM 배지이다. 이후 3T3-L1 세포가 지방세포로 분화가 유도되면, 낮은 농도의 인슐린이 첨가된 배지에 각각의 지방세포에 상기 센티페드그라스(centipedegrass)의 크루드(crude) 추출물, 음성대조군, 에틸아세테이트-50% 및 70%메탄올 분획물을 처리하였다. 상기 지방세포내로 포도당이 유입되어 당대사 과정을 통해 생성되는 지방의 축적되는 양을 오일-레드(Oil Red)-O 염색을 통하여 확인하였다. 오일-레드-O 염색 용액은 지방세포 내 지방만을 특이적으로 염색하는 시약으로 포도당이 분해되고 생합성되는 지방을 염색할 수 있으므로, 각 시료의 지방 생성양을 비교분석할 수 있다. 염료 추출 용액인 이소-프로판올(iso-propanol)을 이용하여 붉게 염색된 용액을 추출 후 O.D. 490 nm에서 측정을 하였다.Adipocyte lines (3T3-L1 Preadipocyte cell line) were used to determine whether ethyl acetate-50% and 70% methanol fractions enhance glucose uptake by adipocytes. Specifically, the fat cell line was purchased from the American Type Culture Collect (ATCC), put the adipocytes (3T3-L1) to 1 × 10 6 in a 6 well plate, so that the cells can grow to 90% Incubated for 24 hours in a CO 2 incubator. Then, the culture medium was discarded and another medium to help differentiation into adipocytes was added to induce differentiation into adipocytes for 48 hours. The composition of the adipocyte differentiation medium was 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 10 nm / ml insulin, 1 μM dexamethasone ( dexamethasone) is a DMEM medium. Then, when 3T3-L1 cells are induced to differentiate into adipocytes, the crude extract of the centipedegrass, a negative control group, ethyl acetate-50 in each adipocytes in a medium containing low concentration of insulin is added. % And 70% methanol fractions were treated. Glucose was introduced into the adipocytes and the accumulated amount of fat produced through the process of glucose metabolism was confirmed through oil-red (Oil Red) -O staining. The oil-red-O staining solution is a reagent that specifically stains only fats in adipocytes, so that glucose can be broken down and biosynthesized, so that the amount of fat produced in each sample can be compared and analyzed. The solution dyed red using iso-propanol, a dye extraction solution, was measured at 490 nm after extraction.
그 결과, 낮은 농도의 인슐린이 처리된 군을 기준으로 하였을 때, 에틸아세테이트-50%메탄올 분획물을 100 ㎍/ml 처리한 군에서 지방세포 내 지방 축적되는 정도가 약 300% 이상 증가하는 결과를 보였다. 이것으로 에틸아세테이트-50%메탄올 분획물은 지방세포가 포도당을 세포 내로 유입하는 것을 증가시켰다(도 2 및 도 3).
As a result, when the low concentration of insulin was treated, the accumulation of fat in adipocytes increased by about 300% in the group treated with 100 μg / ml of ethyl acetate-50% methanol fraction. . This ethyl acetate-50% methanol fraction increased the adipocytes to enter glucose into the cells (Fig. 2 and 3).
<< 실험예Experimental Example 2> 2> 센티페드그라스Sentiped Grass 에틸아세테이트-메탄올 Ethyl acetate-methanol 분획물에In the fraction 의한 실험 동물의 혈당 강하 분석 Hypoglycemic analysis of experimental animals
세티페드그라스 추출 분획물이 2형 당뇨마우스(db / db 마우스)에 혈당 강하 활성을 가지는지 확인하였다. 정상군으로 C57BL/6 마우스를 사용하였고, 당뇨 유발군으로 C57BLKS/J-db / db 마우스를 사용하였다. 두 실험동물 모두 중앙실험동물(주)를 통하여 일본 SLC사에서 수입하였으며, 반입될 당시 주령은 7주령이었다. 동물을 본 연구소 동물실험실에 반입 후, 온도 22℃ 및 습도 50%를 유지하는 상태에서 일주일의 순응기간을 주었다. 이후 9주령을 넘기는 시점부터 꼬리에서 채혈하여 혈당을 확인하였고, 혈당이 350 mg/dL가 넘는 시점인 14주령부터 당뇨활성 검증 실험을 진행하였다. 혈당이 기준치(350 mg/dL)를 넘어선 마우스들을 랜덤하게 섞어 그룹을 분류하였으며 정상군과 유발군에는 옥수수 오일(corn oil)만 매일 경구투여 하였고, 나머지 군은 각 처리군에 맞는 시약 및 샘플을 옥수수 오일에 섞어서 매일 경구투여 하였다. 경구 투여양은 마리당 200~300 μl가 되게 하였다. 시작일로부터 열흘간 연속적으로 시약 및 샘플을 투여하였으며, 이후 2일간 샘플투여를 중단하여 마우스 혈당에 어떠한 변화가 있는지 확인하였고 다시 샘플을 처리하였을 때 혈당의 변화를 관찰하였다. Cetipedgrass extract fractions were confirmed to have hypoglycemic activity in
그 결과, 센티페디그라스 에틸아세테이트-50% 및 70%메탄올 분획물을 열흘간 처리한 군은 당뇨 유발군과 비교하여 70~80%의 혈당 강하효과를 나타내는 것을 확인할 수 있고, 샘플처리를 중단함으로써 마우스의 혈당이 다시 상승하는 것으로 보아 에틸아세테이트-50%및 70%메탄올 분획물은 혈당 강하에 큰 영향을 미친다는 것을 확인하였다(도 4).
As a result, it was confirmed that the group treated with the centipedigrass ethyl acetate-50% and 70% methanol fraction for 10 days showed a blood glucose lowering effect of 70-80% compared to the diabetic group, and the mouse was stopped by stopping the sample treatment. As the blood sugar level of the rising again, ethyl acetate-50% and 70% methanol fractions were confirmed to have a significant effect on the blood sugar drop (Fig. 4).
<< 실험예Experimental Example 3> 3> 센티페드그라스Sentiped Grass 에틸아세테이트-메탄올 Ethyl acetate-methanol 분획물에In the fraction 의한 by 글루코스Glucose 경구 부하 실험( Oral Load Experiment ( OralOral GlucoseGlucose ToleranceTolerance testtest , , OGTTOGTT ) 분석) analysis
글루코스 경구 부하 실험은 당뇨병 진단에 널리 이용되는 실험법으로 공복 상태에서 글루코스를 경구 투여하여 혈당을 확인하는 방법으로 당뇨를 진단하는 방법 중 하나이다. 이 실험에 사용된 실험동물은 중앙실험동물(주)를 통하여 일본 SLC사에서 수입한 C57BLKS/J-db / db 마우스로 센티페디그라스 에틸아세테이트-메탄올 분획물을 이용하여 2주간 항당뇨 실험을 마친 후, 2주간 순화과정을 두고 OGTT에 다시 이용하였다. 실험 진행은 마우스를 18시간 절식시켜 공복상태를 유지하게 하고, 글루코스를 투여하기 30분 전에 샘플(50% 또는 70% 분획물 추출물 ; 10 mg/kg 체중)을 옥수수 오일에 섞어서 경구 투여로 전처리하였다. 그리고 글루코스를 체중 2 g/kg로 경구 투여하고, 이후 30분 감격으로 총 6회 혈당의 변화를 확인하였다.The glucose oral loading test is a widely used method for diagnosing diabetes, and is one of methods for diagnosing diabetes by orally administering glucose in a fasting state to check blood glucose. The experimental animals Central Laboratory Animal Co., Ltd. as a C57BLKS / J- db / db mice imported from Japan SLC Inc. centimeters Phedi glass ethyl acetate through the use in this experiment - then with methanol fractions finished
그 결과, 센티페디그라스 에틸아세테이트-메탄올 분획물을 처리한 마우스는 혈당의 급격한 상승을 비교군과 비교하였을 때 약 25% 감소시켰고, 150분 후 혈당강하 정도가 비교군에 비해 약 60%증가 시키는 것을 확인할 수 있었다. 이는 센티페드그라스 에틸아세테이트-메탄올 분획물이 혈당 조절하는 것을 확인하였다(도 5 및 도 6).
As a result, the mice treated with the centipedigrass ethyl acetate-methanol fraction reduced the sudden increase in blood glucose by about 25% compared with the control group, and after 150 minutes, the blood glucose drop was increased by about 60% compared to the control group. I could confirm it. It was confirmed that the centifed glass ethyl acetate-methanol fractions glycemic control (Figs. 5 and 6).
<< 실험예Experimental Example 4> 4> 센티페드그라스Sentiped Grass 에틸아세테이트-메탄올 Ethyl acetate-methanol 분획물의Fraction 투여량을 Dosage 다르게하여Differently 글루코스 경구 부하 실험( Glucose oral loading experiment OralOral GlucoseGlucose ToleranceTolerance testtest , , OGTTOGTT ) )
정상군으로 C57BL/6 마우스를 사용하였고, 당뇨 유발군으로 C57BLKS/J-db / db 마우스를 사용하였다. 두 실험동물 모두 중앙실험동물(주)를 통하여 일본 SLC사에서 수입하였으며, 반입될 당시 주령은 7주령이었다. 동물을 본 연구소 동물실험실에 반입 후, 온도 22℃ 및 습도 50%를 유지하는 상태에서 일주일의 순응기간을 주었다. 실험을 시작하기 전, 12시간동안 절식시켜 공복상태를 유지하였다. 글루코스를 투여하기 30분전에 샘플(클루드 또는 50% 또는 70% 분획물 추출물; 1 mg/kg 또는 10 mg/kg 체중)을 옥수수 오일에 섞어서 경구 투여로 전처리하였다. 그리고 글루코스는 체중당 2 g/kg로 경구 투여하고, 이후 30분 간격 총 6회 혈당의 변화를 확인하였다. C57BL / 6 mice were used as a normal group, and C57BLKS / J- db / db mice were used as a diabetic induction group. Both test animals were imported from Japan's SLC Co., Ltd. through the Central Test Animal Co., Ltd., and the age of import was 7 weeks. After the animals were brought into the laboratory of the laboratory, they were allowed to acclimate for one week while maintaining the temperature of 22 ° C. and the humidity of 50%. Before starting the experiment, fasted for 12 hours to maintain an empty stomach. Thirty minutes prior to administration of glucose, samples (clude or 50% or 70% fraction extracts; 1 mg / kg or 10 mg / kg body weight) were mixed with corn oil and pretreated by oral administration. Glucose was orally administered at 2 g / kg body weight, and then the change in
그 결과, 센티페디그라스 에틸아세테이트-50%메탄올 분획물을 처리한 군이 비교군에 비해 60분 후 혈당이 급격히 상승하는 것을 고농도에서는 40%, 저농도에서는 60% 수준으로 유지하는 것을 확인하였다(도 7).
As a result, it was confirmed that the group treated with the centipedigrass ethyl acetate-50% methanol fraction maintained a rapid increase in blood glucose after 60 minutes compared with the comparative group at a high concentration of 40% and a low concentration of 60% (FIG. 7). ).
<< 실험예Experimental Example 5> 5> 센티페드그라스Sentiped Grass 에틸아세테이트-메탄올 Ethyl acetate-methanol 분획물의Fraction 투여량을 Dosage 다르게하여Differently 복강내 당 부하 검사( Intraperitoneal sugar load test ( IntraperitonealIntraperitoneal tolerancetolerance testtest , , IPGTTIPGTT ) 분석) analysis
정상군으로 C57BL/6 마우스를 사용하였고, 당뇨 유발군으로 C57BLKS/J-db / db 마우스를 사용하였다. 두 실험동물 모두 중앙실험동물(주)를 통하여 일본 SLC사에서 수입하였으며, 반입될 당시 주령은 7주령이었다. 동물을 본 연구소 동물실험실에 반입 후, 온도 22℃ 및 습도 50%를 유지하는 상태에서 일주일의 순응기간을 주었다. 실험을 시작하기 전, 12 시간 동안 절식시켜 공복상태를 유지하였다. 글루코스를 투여하기 30분 전에 샘플(클루드 또는 50% 또는 70% 분획물 추출물 ; 1 mg/kg 또는 10 mg/kg 체중)을 10 mM KOH에 녹여 복강 투여로 전처리하였다. 그리고 글루코스는 체중 2 g/kg로 복강 투여하고, 이후 30분 간격 총 6회 혈당의 변화를 확인하였다. C57BL / 6 mice were used as a normal group, and C57BLKS / J- db / db mice were used as a diabetic induction group. Both test animals were imported from Japan's SLC Co., Ltd. through the Central Test Animal Co., Ltd., and the age of import was 7 weeks. After the animals were brought into the laboratory of the laboratory, they were allowed to acclimate for one week while maintaining the temperature of 22 ° C. and the humidity of 50%. Before starting the experiment, fasted for 12 hours to maintain an empty stomach. Thirty minutes prior to administration of glucose, samples (clude or 50% or 70% fraction extracts; 1 mg / kg or 10 mg / kg body weight) were dissolved in 10 mM KOH and pretreated by intraperitoneal administration. Glucose was intraperitoneally administered at a weight of 2 g / kg, after which a total change in blood glucose was confirmed 6 times every 30 minutes.
그 결과, 센티페디그라스 에틸아세테이트-50%메탄올 분획물을 고농도 및 저농도로 처리한 군을 비교군과 비교를 하였을 때, 2시간 후 혈당강하 정도가 약 80% 증가되는 것을 확인하였다(도 8).
As a result, when comparing the group treated with high concentration and low concentration of centipedigrass ethyl acetate-50% methanol fraction with the comparison group, it was confirmed that the blood sugar drop degree is increased by about 80% after 2 hours (Fig. 8).
<< 실험예Experimental Example 6> 6> 센티페드그라스Sentiped Grass 에틸아세테이트-메탄올 Ethyl acetate-methanol 분획물을The fraction 복강 투여한 다음 After intraperitoneal administration 글루코스Glucose 경구 부하 실험( Oral Load Experiment ( OralOral GlucoseGlucose ToleranceTolerance testtest , , OGTTOGTT ) 분석) analysis
당뇨 유발 마우스는 C57BLKS/J-db / db 마우스를 사용하였다. 실험동물은 중앙실험동물(주)를 통하여 일본 SLC사에서 수입하였으며, 반입될 당시 주령은 7주령이었다. 동물을 본 연구소 동물실험실에 반입 후, 온도 22℃ 및 습도 50%를 유지하는 상태에서 일주일의 순응기간을 주었다. 실험을 시작하기 전, 12 시간 동안 절식시켜 공복상태를 유지하였다. 글루코스를 투여하기 30 분전에 샘플(클루드 또는 50% 또는 70% 분획물 추출물 ; 1 mg/kg 또는 50 mg/kg 체중)을 10 mM KOH에 녹여 복강 투여로 전처리하였고, 글루코스는 체중당 2 g/kg로 경구 투여하였다. 이때 투여되는 양은 각각 200 μl가 되도록 하였다. 5시간 동안 총 9회 혈당의 변화를 확인하였다.Diabetes-induced mice used C57BLKS / J- db / db mice. The experimental animals were imported from SLC, Japan through the Central Experimental Animal Co., Ltd., and the age was 7 weeks of age. After the animals were brought into the laboratory of the laboratory, they were allowed to acclimate for one week while maintaining the temperature of 22 ° C. and the humidity of 50%. Before starting the experiment, fasted for 12 hours to maintain an empty stomach. Thirty minutes before the administration of glucose, the sample (clude or 50% or 70% fraction extract; 1 mg / kg or 50 mg / kg body weight) was dissolved in 10 mM KOH and pretreated by intraperitoneal administration, and glucose was 2 g / kg body weight. oral administration in kg. The amount to be administered was set to 200 μl each. A total of 9 changes in blood glucose were confirmed for 5 hours.
그 결과, 4시간 30분이 지난 시점에서 대조군의 혈당은 400 mg/dL이상으로 유지되고 있지만, 센티페디그라스 에틸아세테이트-50%메탄올 분획물을 처리한 군의 혈당은 250 mg/dL이하까지 떨어졌다. 이것은 대조군과 비교하여 혈당강하 정도가 약 60% 증가하였다(도 9).
As a result, after 4 hours and 30 minutes, the blood sugar of the control group was maintained at 400 mg / dL or more, but the blood sugar of the group treated with centipedigrass ethyl acetate-50% methanol fraction dropped to 250 mg / dL or less. This increased about 60% of the level of hypoglycemia compared to the control (Fig. 9).
<<
실험예Experimental Example
7> 7>
센티페드그라스Sentiped Grass
에틸아세테이트-메탄올 Ethyl acetate-methanol
분획물에In the fraction
의한 스트렙토조토신( Streptozotocin caused by
STZSTZ
)-제 1형 당뇨 유도 모델에서 In the
당뇨가 유도된 ICR 마우스를 이용하여 스트렙토조토신(streptozotocin, STZ)-제 1형 당뇨 유도 모델에서 센티페드그라스 추출물들이 항당뇨 활성을 가지는지 확인하는 실험을 진행하였다. 실험동물은 중앙실험동물(주)을 통하여 일본 SLC사에서 수입하였으며, 반입될 당시 주령은 7주령이었다. 동물을 본 연구소 동물실험실에 반입 후, 온도 22℃ 및 습도 50%를 유지하는 상태에서 일주일의 순응기간을 주었다. 1형 당뇨 모델은 STZ를 이용하여 췌장의 베타세포만을 특이적으로 파괴하여 인슐린분비를 저하시켜 유도하였다. STZ를 50 mM 시트르산 완충액(citrate buffer)(pH 4.5)에 녹여 복강투여를 통해 1형 당뇨를 유도하게 되는데, 체중 80 mg/kg가 되도록 하여 이틀 간격으로 3회 주사하였다. 3일 후 혈당을 확인하여 혈당이 350 mg/dL가 넘는 마우스를 선발하여 무작위로 섞어 실험에 이용하였다. 실험을 시작하기 전, 12시간 동안 절식시켜 공복상태를 유지하였다. 글루코스를 투여하기 30분 전에 샘플(50% 또는 70% 분획물 추출물 ; 20 mg/kg 체중)을 옥수수 오일에 섞어서 경구 투여로 전처리하였고, 이후 글루코스는 체중당 2 g/kg로 경구 투여하였다. 혈당 확인은 6 시간 동안 총 10회 혈당의 변화를 확인하였다.An experiment was conducted to determine whether the centipedes grass extracts had antidiabetic activity in a streptozotocin (STZ) -
그 결과, 센티페디그라스 에틸아세테이트-메탄올 분획물을 처리한 군은 4시간 30분이 지나는 시점부터 혈당이 정상군과 같은 정도까지 떨어지는 것을 확인할 수 있다. 하지만, 대조군은 6시간이 지나도 정상군보다 150 mg/dL이상 높게 유지되고, 글루코스를 투여하고 6 시간 후 센티페디그라스 에틸아세테이트-메탄올 분획물을 처리한 군은 대조군과 비교하여 100% 혈당강하시켰다(도 10).
As a result, the group treated with the centipedigrass ethyl acetate-methanol fraction can confirm that the blood sugar drops to the same level as the normal group from 4 hours and 30 minutes. However, the control group maintained 150 mg / dL higher than the normal group even after 6 hours, and 6 hours after the administration of glucose, the group treated with the centipidigras ethylacetate-methanol fraction lowered blood glucose by 100% compared to the control group ( 10).
<제조예 1> 센티페드그라스 추출물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 약제의 제조<Preparation Example 1> Preparation of a medicament for preventing and treating diabetes containing centipedegrass extract as an active ingredient
<제제예 1> 약학적 제제의 제조≪ Formulation Example 1 > Preparation of pharmaceutical preparation
<1-1><1-1> 산제의 제조Manufacture of Powder
실시예 <1-1> 센티페드그라스 메탄올 추출물 0.1 gExample < 1-1 > A mixture of 0.1 g of Centipede Grass methanol extract
유당 1.5 gLactose 1.5 g
탈크 0.5 gTalc 0.5 g
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above ingredients were mixed and filled in an airtight container to prepare powders.
<1-2> 정제의 제조<1-2> Preparation of tablets
본 발명의 센티페드그라스 추출물을 유효성분으로 함유하는 정제는 하기 표 3의 조성과 같이 제조하였다.Tablets containing the centipedegrass extract of the present invention as an active ingredient were prepared as shown in Table 3 below.
본 발명의 추출물 250 중량부, 락토오스 175.9 중량부, 감자전분 180 중량부 및 콜로이드성 규산 32 중량부와 혼합하였다. 상기 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄하여 14 매쉬체를 통과시켰다. 이것을 건조하고 여기에 감자전분 160 중량부, 활석 50 중량부 및 스테아린산 마그네슘 5 중량부를 첨가하여 얻은 혼합물을 정제로 제조하였다.
250 parts by weight of the extract of the present invention, 175.9 parts by weight of lactose, 180 parts by weight of potato starch and 32 parts by weight of colloidal silicic acid. 10% gelatin solution was added to the mixture, followed by pulverization and passed through a 14-mesh sieve. This was dried, to which 160 parts by weight of potato powder, 50 parts by weight of talc and 5 parts by weight of magnesium stearate were added, and the resulting mixture was purified.
<1-3><1-3> 캡슐제의 제조 Preparation of capsules
실시예 <1-1> 센티페드그라스 메탄올 추출물 0.1 gExample < 1-1 > A mixture of 0.1 g of Centipede Grass methanol extract
옥수수전분 5 gCorn starch 5 g
카르복시 셀룰로오스 4.9 g4.9 g of carboxycellulose
상기의 성분들을 혼합하여 분말을 제조한 후, 상기 분말을 통상의 캡슐제의 제조방법에 따라 경질 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components to prepare a powder, the powder was filled in a hard capsule according to a conventional preparation method of a capsule to prepare a capsule.
<1-4> 주사제의 제조≪ 1-4 > Preparation of injection
실시예 <1-1> 센티페드그라스 메탄올 추출물 0.1 gExample < 1-1 > A mixture of 0.1 g of Centipede Grass methanol extract
주사용 멸균 증류수 적량Sterile sterilized water for injection
pH 조절제 적량pH adjuster
통상의 주사제의 제조방법에 따라 1 앰플 당(2 ㎖) 상기의 성분 함량으로 제조하였다.
(2 ml) per ampoule according to the usual injection preparation method.
<1-5><1-5> 액제의 제조Manufacture of liquid agent
실시예 <1-1> 센티페드그라스 메탄올 추출물 0.1 gExample < 1-1 > A mixture of 0.1 g of Centipede Grass methanol extract
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고, 레몬향을 적량 가한 다음 상기의 성분을 혼합하였다. 그 다음 정제수를 가하여 전체 100 로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조하였다.
Each component was dissolved in purified water in accordance with a conventional method for producing a liquid agent, and the lemon flavor was added in an appropriate amount, followed by mixing the above components. Then, purified water was added to adjust the total amount to 100, and the solution was filled in a brown bottle and sterilized to prepare a liquid preparation.
<1-6> 시럽제의 제조≪ 1-6 > Preparation of syrup preparation
본 발명의 센티페드그라스 추출물을 유효성분으로 함유하는 시럽제는 하기 표 2의 조성과 같이 제조하였다.Syrup containing the centipedegrass extract of the present invention as an active ingredient was prepared as shown in Table 2.
<제조예 2> 센티페드그라스 추출물을 유효성분으로 함유하는 건강식품의 제조Preparation Example 2 Preparation of Health Foods Containing Centipedgrass Extract as Active Ingredient
<2-1> 밀가루 식품의 제조<2-1> Production of flour food
상기 실시예 <1-3>의 센티페드그라스 물 추출물 0.5 ~ 5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다.
0.5-5.0 parts by weight of the centipedglass water extract of Example <1-3> was added to wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers and noodles.
<2-2> 스프 및 육즙(gravies)의 제조<2-2> Production of soups and gravies
상기 실시예 <1-3>의 센티페드그라스 물 추출물 0.1 ~ 5.0 중량부를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.
0.1 to 5.0 parts by weight of the centipedglass water extract of Example <1-3> was added to the soup and the juice to prepare a health promotion meat product, noodle soup and juice.
<2-3> 그라운드 비프(ground beef)의 제조<2-3> Preparation of ground beef
상기 실시예 <1-3>의 센티페드그라스 물 추출물 10 중량부를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.
10 parts by weight of the centipede water extract of Example <1-3> was added to the ground beef to prepare ground beef for health promotion.
<2-4> 유제품(dairy products)의 제조<2-4> Production of Dairy Products
상기 실시예 <1-3>의 센티페드그라스 물 추출물 5 ~ 10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
5-10 parts by weight of the centipedglass water extract of Example <1-3> was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<2-5> 선식의 제조≪ 2-5 >
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
상기 실시예 <1-3>의 센티페드그라스 물 추출물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The centipede water extract of Example <1-3> was concentrated under reduced pressure in a vacuum concentrator, dried by spraying and dried in a hot air drier, and pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 실시예 <1-3>의 센티페드그라스 물 추출물을 다음의 비율로 배합하여 제조하였다.The above-prepared cereals, seeds and centipede water extract of Example <1-3> were prepared in the following proportions.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
실시예 <1-3>의 추출물(3 중량부),The extract (3 parts by weight) of Example <1-3>,
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 중량부)
(0.5 parts by weight)
<제조예 3> 센티페드그라스 추출물을 유효성분으로 함유하는 기능성 음료의 제조Preparation Example 3 Preparation of Functional Drink Containing Centipedgrass Extract as Active Ingredient
<3-1> 건강 음료의 제조<3-1> Production of health drinks
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명의 센티페드그라스 추출물 5 g을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 제조하였다.
(5%) of the centipede glass extract of the present invention was homogeneously mixed with a mixture of liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5% And packaged in small containers such as glass bottles and plastic bottles.
<3-2> 야채 주스의 제조<3-2> Preparation of vegetable juice
본 발명의 센티페드그라스 추출물 5 g을 토마토 또는 당근 주스 1,000 ㎖에 가하여 야채 주스를 제조하였다.Vegetable juice was prepared by adding 5 g of centifedgrass extract of the present invention to 1,000 ml of tomato or carrot juice.
<3-3> 과일 주스의 제조<3-3> Production of fruit juice
본 발명의 센티페드그라스 추출물 1 g을 사과 또는 포도 주스 1,000 ㎖ 에 가하여 과일 주스를 제조하였다.1 g of centifedgrass extract of the present invention was added to 1,000 ml of apple or grape juice to prepare a fruit juice.
Claims (14)
Centipede grass (Centipede grass, Eremochloa ophiuroides ) water, C 1 to C 2 low alcohol or a mixed solvent extract thereof comprising as an active ingredient a pharmaceutical composition for preventing and treating diabetes.
The pharmaceutical composition for preventing and treating diabetes of claim 1, wherein the lower alcohol is ethanol or methanol.
[Claim 2] The pharmaceutical composition for preventing and treating diabetes of claim 1, wherein the water of Centipedgrass, C 1 to C 2 lower alcohol, or a mixed solvent extract thereof is extracted with hot water.
A pharmaceutical composition for preventing and treating diabetes comprising the fraction prepared by additionally extracting centipedes grass extract with n-hexane or ethyl acetate as an active ingredient.
6. The pharmaceutical composition for preventing and treating diabetes of claim 5, wherein the fraction is an ethyl acetate fraction obtained by extracting the centifed glass methanol extract with n-nucleic acid and removing the soluble layer with ethyl acetate.
6. The pharmaceutical composition for preventing and treating diabetes of claim 5, wherein the fraction comprises an active fraction obtained by additionally extracting the ethyl acetate fraction of the centipedegrass methanol extract with methanol as an active ingredient.
9. The pharmaceutical composition for preventing and treating diabetes of claim 8, wherein the methanol is 20% to 70% by weight methanol in the total aqueous solution.
10. The pharmaceutical according to any one of claims 1, 3 to 5 or 7 to 9, wherein the diabetes is type 1 diabetes or type 2 diabetes. Composition.
A functional food for preventing and ameliorating diabetes, comprising the water of sentigraphgrass of claim 1 , a lower alcohol of C 1 to C 2 or a mixed solvent extract thereof, a fraction of claim 5, or an active fraction of claim 8 as an active ingredient.
12. The functional food for preventing and improving diabetes of claim 11, wherein the diabetes is type 1 diabetes or type 2 diabetes.
A pharmaceutical composition for controlling blood sugar drop, comprising the water of Centipegrass of claim 1 , a lower alcohol of C 1 to C 2 or a mixed solvent extract thereof, a fraction of claim 5 or an active fraction of claim 8 as an active ingredient.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120102684A KR101350826B1 (en) | 2012-09-17 | 2012-09-17 | Composition for the prevention and treatment of diabetes mellitus comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
CN201810159065.9A CN108295198B (en) | 2012-09-17 | 2012-11-26 | Composition comprising an extract of eremochloa ophiuroides or a fraction thereof as an active ingredient |
PCT/KR2012/010024 WO2014042316A1 (en) | 2012-09-17 | 2012-11-26 | Composition comprising centipede grass extracts or fractions thereof as active ingredients |
EP12884368.7A EP2898892B1 (en) | 2012-09-17 | 2012-11-26 | Composition comprising centipede grass extracts or fractions thereof as active ingredients |
CN201280076849.6A CN104812399B (en) | 2012-09-17 | 2012-11-26 | Include the composition of ciliate desert-grass extract or its position as active constituent |
EP15186313.1A EP3042663B1 (en) | 2012-09-17 | 2012-11-26 | Composition comprising centipede grass extracts or fractions thereof as active ingredients |
US14/435,127 US9655941B2 (en) | 2012-09-17 | 2012-11-26 | Composition comprising centipede grass extracts or fractions thereof as active ingredients |
US15/167,885 US10052358B2 (en) | 2012-09-17 | 2016-05-27 | Composition comprising centipede grass extracts or fractions thereof as active ingredients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120102684A KR101350826B1 (en) | 2012-09-17 | 2012-09-17 | Composition for the prevention and treatment of diabetes mellitus comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101350826B1 true KR101350826B1 (en) | 2014-01-14 |
Family
ID=50145398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120102684A KR101350826B1 (en) | 2012-09-17 | 2012-09-17 | Composition for the prevention and treatment of diabetes mellitus comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101350826B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101797717B1 (en) | 2015-11-16 | 2017-11-14 | 한국원자력연구원 | A pharmaceutical composition comprising derhamnosylmasin or pharmaceutically acceptable salt thereof as an active ingredient for prevention and treatment of diabetes mellitus |
WO2018110875A1 (en) | 2016-12-12 | 2018-06-21 | Korea Atomic Energy Research Institute | Pharmaceutical composition for the prevention or treatment of alopecia comprising eremochloa ophiuroides extract or fractions thereof as an active ingredient |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110054746A (en) * | 2009-11-18 | 2011-05-25 | 한국원자력연구원 | A composition for skin anti-aging comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
KR101077916B1 (en) | 2010-04-26 | 2011-10-31 | 한국원자력연구원 | Pharmaceutical compositions for prevention and treatment of obesity comprising extract of eremochloa ophiuroides as an active ingredient |
-
2012
- 2012-09-17 KR KR1020120102684A patent/KR101350826B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110054746A (en) * | 2009-11-18 | 2011-05-25 | 한국원자력연구원 | A composition for skin anti-aging comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
KR101077916B1 (en) | 2010-04-26 | 2011-10-31 | 한국원자력연구원 | Pharmaceutical compositions for prevention and treatment of obesity comprising extract of eremochloa ophiuroides as an active ingredient |
Non-Patent Citations (4)
Title |
---|
H.-W. Bai et al. 2012 International Conference on Biomedical Engineering and Biotechnology. pp187-189 (2012.05.28~30.) * |
H.-W. Bai et al. 2012 International Conference on Biomedical Engineering and Biotechnology. pp187-189 (2012.05.28~30.)* |
대덕넷 뉴스. "원자력연, 잔디 성분 이용 화장품 개발" 2012.07.12. (인터넷 URL: http://www.hellodd.com/Kr/DD_News/Article_View.asp?Mark=38417) * |
대덕넷 뉴스. "원자력연, 잔디 성분 이용 화장품 개발" 2012.07.12. (인터넷 URL: http://www.hellodd.com/Kr/DD_News/Article_View.asp?Mark=38417)* |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101797717B1 (en) | 2015-11-16 | 2017-11-14 | 한국원자력연구원 | A pharmaceutical composition comprising derhamnosylmasin or pharmaceutically acceptable salt thereof as an active ingredient for prevention and treatment of diabetes mellitus |
WO2018110875A1 (en) | 2016-12-12 | 2018-06-21 | Korea Atomic Energy Research Institute | Pharmaceutical composition for the prevention or treatment of alopecia comprising eremochloa ophiuroides extract or fractions thereof as an active ingredient |
US11241471B2 (en) | 2016-12-12 | 2022-02-08 | Korea Atomic Energy Research Institute | Pharmaceutical composition for the prevention or treatment of alopecia comprising Eremochloa ophiuroides extract or fractions thereof as an active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070166320A1 (en) | Agent for preventing/ameliorating diabetes and functional food for preventing/ameliorating diabetes | |
KR101144059B1 (en) | Composition for prevention or treatment of diabete or obesity comprising Punica granatum extract and red ginseng extract | |
KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
KR20130064882A (en) | The composition for the prevention and treatment of diabetic or diabetic complications containing the extracts of herbal medicine | |
KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
KR102644808B1 (en) | Composition for preventing, ameliorating or treating metabolic disease comprising leaf extract of new pepper cultivar as effective component | |
KR101261029B1 (en) | Composition for preventing or improving the diabete containing suaeda japonica | |
KR101616811B1 (en) | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa | |
KR101350826B1 (en) | Composition for the prevention and treatment of diabetes mellitus comprising extracts or fractions of eremochloa ophiuroides as an active ingredient | |
KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
KR102292059B1 (en) | Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes | |
KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
KR100824365B1 (en) | Composition comprising the extracts, fractions and the isolated compounds of phyllostachys nigra munro for prevention or treatment of diabetic complications | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
KR101414040B1 (en) | Pharmaceutial composition comprising silkworm extract for regulation of blood glucose, herbal medicine and health food | |
KR101134781B1 (en) | Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus | |
KR102639283B1 (en) | A Composition For Preventing, Improving Or Treating Gastrointestinal Disorders Including Dry Ginger Extract And Pomegranate Extract | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
US20070092587A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
KR102682338B1 (en) | A Composition For Preventing, Improving Or Treating Gastrointestinal Disorders Including Extract Of Eucommia Ulmoides Oliver And Extract Of Citrus Unshiu | |
KR102606384B1 (en) | Composition for anti-obesity comprising a compound derived from red bean bud | |
KR102522975B1 (en) | An anti-obesity composition containing a fermented Moringa oleifera extract produced using a novel Monascus purpureus SL1 strain as an active ingredient | |
KR102234225B1 (en) | Pharmaceutical Composition Comprising Extracts of Eucommia ulmoides Oliver and Achyranthes japonica for Preventing or Treating Obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20171207 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190104 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 7 |